You are running an unsupported browser, please upgrade your browser. Close

Adeno-Associated Virus (AAV) Production

End-to-end process support, from development to industrialization

Adeno-associated viral (AAV) vectors are the most commonly used delivery system for gene therapies currently under development. AAV comes in a wide range of serotypes, which allows for targeting different types of tissue specifically. Other advantages include that it is non-pathogenic and cannot replicate on its own, which increases safety; and its ability to transduce non-dividing and dividing cells. 

 

Much progress has been made in developing commercial production-scale processes for gene therapies in recent decades, but challenges persist, especially around upscaling. We offer a wide range of robust, scalable solutions and have the technical knowledge and experience to help you every step of the way. 

 

Most AAV vector production follows the same basic process, with some variation as needed.   

 

 

Upstream

     

 

 

Downstream

     

Bioburden Filtration
Purification
(Chromatography)
Neutralization
/Dilution
Polishing
(Chromatography)



 

Poster: Scaling-Up and Industrializing the Production of Viral Vectors and Cells for Therapeutic Use

 

Download

 

Upstream

Adherent Cell Seeding

Adherent Cell Culture

Suspension Cell Culture

Clarification

Want to learn more about 

Upstream Process 

workflows? 

Speak to an expert

 

Downstream

Bioburden Filtration

UF/DF

Polishing (Chromatography)

Bulk Drug Substance Filtration

Want to learn more about 

Downstream Process 

workflows? 

Speak to an expert

 

Complementary Technologies

Connect With An Expert

 

 

 

 

Pall has a global team of over 300 experienced technical professionals to support your molecule from pre-clinical to commercial manufacturing. From process development services and end-to-end platforms, to on-site testing and applications support for specific process steps, Pall will help you find the best solution based on data and testing.